MEI Pharma’s Board of Directors has unanimously adopted a strategic plan focused on prioritizing the clinical development of voruciclib, a CDK9 inhibitor, and a new formulation of ME-344, a novel therapeutic strategy.
To ensure sufficient resources for these programs, the Board has decided not to pursue a second capital return under the Anson and Cable Car Cooperation Agreement. This decision aims to conserve capital and align with the Company’s strategic investment priorities, extending its operational runway.
Both voruciclib and ME-344 have demonstrated promising clinical data. Voruciclib, combined with venetoclax, is being developed to treat relapsed/refractory AML without actionable mutations, offering a potential broader impact than mutation-specific therapies. ME-344 has the potential to treat various solid tumors through a novel strategy that involves synthetic lethality in tumor cells.
MEI Pharma’s leadership team is highly experienced in clinical development and is confident in executing this strategy. The Company believes that this focus on clinical programs, coupled with capital conservation, will create long-term value for shareholders and advance the fight against cancer.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
